
Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics
2025-11-10 15:55:39Prestige Consumer Healthcare, Inc. has adjusted its valuation amid shifts in financial metrics and market standing within the Pharmaceuticals & Biotechnology sector. The company displays various profitability ratios and has faced performance challenges this year, contrasting with the broader market and highlighting the competitive landscape and differing risk profiles among peers.
Read full news article
Prestige Consumer Healthcare Stock Hits New 52-Week Low at $59.62
2025-11-03 17:06:31Prestige Consumer Healthcare, Inc. has reached a new 52-week low, trading at USD 59.62 as of October 31, 2025. The company has seen a 7.75% decline over the past year, contrasting with the S&P 500's performance. Financial metrics show mixed results, with high institutional ownership and recent low quarterly sales figures.
Read full news article
Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Landscape
2025-11-03 15:53:10Prestige Consumer Healthcare, Inc. has adjusted its valuation, showcasing a P/E ratio of 20 and a price-to-book value of 2.48. The company demonstrates solid profitability with a ROCE of 12.76% and ROE of 12.16%, positioning it competitively within the pharmaceuticals and biotechnology sector.
Read full news article
Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Metrics
2025-10-27 15:53:58Prestige Consumer Healthcare, Inc. has adjusted its valuation within the pharmaceuticals and biotechnology sector, with key metrics indicating operational efficiency and profitability. The company's performance has fluctuated, showing a decline over the past year compared to the broader market, highlighting challenges in the current environment.
Read full news article





